Detalles MARC
| 000 -CABECERA |
|---|
| Longitud fija campo de control |
04682nam a2200265ui 4500 |
| 001 - NÚMERO DE CONTROL |
|---|
| Número de control |
ZaR2020001317 |
| 008 - CÓDIGOS DE INFORMACIÓN DE LONGITUD FIJA |
|---|
| Códigos de información de longitud fija |
201009s2013 us f 001 0 eng d |
| 020 ## - NÚMERO INTERNACIONAL NORMALIZADO PARA LIBROS |
|---|
| Número Internacional Normalizado para Libros (ISBN) |
9780123942951 |
| 040 ## - FUENTE DE LA CATALOGACIÓN |
|---|
| Centro catalogador |
UCA-CYT |
| Lengua de catalogación |
spa |
| 245 00 - MENCIÓN DE TÍTULO |
|---|
| Título |
Gene therapy of cancer : |
| Resto del título |
translational approaches from preclinical studies to clinical implementation / |
| Mención de responsabilidad, etc. |
edited by Edmund C. Lattime, Stanton L. Gerson |
| 250 ## - MENCIÓN DE EDICIÓN |
|---|
| Mención de edición |
3rd ed. |
| 260 ## - PUBLICACIÓN, DISTRIBUCIÓN, ETC. (PIE DE IMPRENTA) |
|---|
| Lugar de publicación, distribución, etc. |
San Diego : |
| Nombre del editor, distribuidor, etc. |
Academic Press, |
| Fecha de publicación, distribución, etc. |
2013 |
| 300 ## - DESCRIPCIÓN FÍSICA |
|---|
| Extensión |
XV, 537 p. ; |
| Dimensiones |
28 cm. |
| 500 ## - NOTA GENERAL |
|---|
| Nota general |
Índice |
| 504 ## - NOTA DE BIBLIOGRAFÍA, ETC |
|---|
| Nota de bibliografía, etc. |
Bibliografía |
| 520 ## - NOTA DE SUMARIO |
|---|
| Sumario, etc, |
Gene therapy as a treatment for cancer is at a critical point in its evolution. Exciting new developments in gene targeting and vector technology, coupled with results from the first generation of preclinical and clinical studies have led to the design and testing of new therapeutic approaches. The Third Edition of Gene Therapy of Cancer provides crucial updates on the basic and applied sciences of gene therapy. It offers a comprehensive assessment of the field including the areas of suicide gene therapy, oncogene and suppressor gene targeting, immunotherapy, drug resistance gene therapy, and the genetic modification of stem cells. Researchers at all levels of development, from basic laboratory investigators to clinical practitioners, will find this book to be instructive. Cancer gene therapy, like cancer therapy in general, is evolving rapidly, testing new concepts, targets and pathways, evoking new technologies, and passing new regulatory hurdles. Its essence, however, has not changed: the hope and challenges of returning altered genes to normal, using targeted gene expression to alter the function of both tumor and microenvironment, and in some cases normal cells, and delivering functionally important genes to specific cell types to increase sensitivity to killing or to protect normal cells from cancer therapies. In some instances, gene therapy for cancer forms a continuum from gene repair through the use of molecularly modified cells; the use of viral and non-viral vector based gene delivery to both tumor and tumor microenvironment; the use of viral and gene based vaccines; and development of new gene-based therapeutics. The unique mechanistically chosen vector platforms are at the heart of this technology because they allow for direct and selective cell death and transient to sustained delivery of vaccine molecules or molecules that affect the microenvironment, vasculature, or the immune response. <br/>Explains the underlying cancer biology necessary for understanding proposed therapeutic approaches Presents in-depth description of targeting systems and treatment strategiesCovers the breadth of gene therapy approaches including immunotherapeutic, drug resistance,oncolytic viruses, as well as regulatory perspectives from both the NCI and FDA<br/>INDICE: Introduction; Overview of Viral and Non-Viral Vector Technologies; DNA Integration for Monitoring Outcome in Gene Therapy; Multiple Treatment Cycles and Gene Therapy; RNA interference-based therapy for cancer; Targeted systemic delivery of therapeutic siRNA; Lentiviral-vector Common Integration Sites; Selective Replicating Adenovirus and Tumor Necrosis; Cancer Suicide Gene Therapy; Adenovirus-retrovirus Hybrid Vectors ; Electroporation gene therapy; Biomaterials-based technologies for therapeutics and imaging; RNA Inhibition gene therapy; Monocytogenes-based DNA Delivery System; Toxin based Cancer Gene Therapy; Overview: Rationale use of oncolytic virus in clinic |
| 650 04 - PUNTO DE ACCESO ADICIONAL DE MATERIA - TÉRMINO DE MATERIA |
|---|
| Término de materia o nombre geográfico como elemento inicial |
Terapia génica |
| 9 (RLIN) |
3946 |
| 650 04 - PUNTO DE ACCESO ADICIONAL DE MATERIA - TÉRMINO DE MATERIA |
|---|
| Término de materia o nombre geográfico como elemento inicial |
Oncología |
| 9 (RLIN) |
4541 |
| 650 04 - PUNTO DE ACCESO ADICIONAL DE MATERIA - TÉRMINO DE MATERIA |
|---|
| Término de materia o nombre geográfico como elemento inicial |
Cáncer |
| 9 (RLIN) |
3912 |
| Subdivisión de materia general |
Tratamiento |
| 700 1# - PUNTO DE ACCESO ADICIONAL - NOMBRE DE PERSONA |
|---|
| Nombre de persona |
Lattime, Edmund C., |
| Término indicativo de función |
editor |
| 700 1# - PUNTO DE ACCESO ADICIONAL - NOMBRE DE PERSONA |
|---|
| Nombre de persona |
Gerson, Stanton L., |
| Término indicativo de función |
editor |
| 907 ## - CÓDIGO DE CATALOGADOR |
|---|
| Catalogador/a |
84zar |
| 942 ## - ENTRADA DE ELEMENTOS AGREGADOS (KOHA) |
|---|
| Fuente de clasificaión o esquema |
Clasificación Decimal Universal |
| Suprimir del OPAC |
No |